{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:54:17Z","timestamp":1790805257025,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the\n                    <jats:italic>TP53<\/jats:italic>\n                    gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable\n                    <jats:italic>TP53-<\/jats:italic>\n                    related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotype\u2013phenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the\n                    <jats:italic>TP53<\/jats:italic>\n                    gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals.\n                  <\/jats:p>","DOI":"10.1007\/s12094-023-03202-9","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T01:01:37Z","timestamp":1683075697000},"page":"2627-2633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-5374","authenticated-orcid":false,"given":"Ana Beatriz","family":"S\u00e1nchez-Heras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-3585","authenticated-orcid":false,"given":"Teresa","family":"Ramon y Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-5845","authenticated-orcid":false,"given":"Marta","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-5959","authenticated-orcid":false,"given":"Elena","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-8188","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-3276","authenticated-orcid":false,"given":"Isabel","family":"Chirivella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-6415","authenticated-orcid":false,"given":"Judit","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-3512","authenticated-orcid":false,"given":"Joan","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SEOM Hereditary Cancer Working Group and AEGH Hereditary Cancer Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","volume":"22","author":"KC de Andrade","year":"2021","unstructured":"de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, et al. Cancer incidence, patterns, and genotype\u2013phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021;22:1787\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(21)00580-5.","journal-title":"Lancet Oncol"},{"key":"3202_CR2","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort: cancer risk in TP53 mutation carriers. Cancer. 2016;122:3673\u201381. https:\/\/doi.org\/10.1002\/cncr.30248.","journal-title":"Cancer"},{"key":"3202_CR3","doi-asserted-by":"publisher","first-page":"a026187","DOI":"10.1101\/cshperspect.a026187","volume":"7","author":"T Guha","year":"2017","unstructured":"Guha T, Malkin D. Inherited TP53 mutations and the Li\u2013Fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7:a026187. https:\/\/doi.org\/10.1101\/cshperspect.a026187.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3202_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"The European Reference Network GENTURIS, Frebourg T, BajalicaLagercrantz S, Oliveira C, Magenheim R, Evans DG. Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379\u201386. https:\/\/doi.org\/10.1038\/s41431-020-0638-4.","journal-title":"Eur J Hum Genet"},{"key":"3202_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/humu.24152","volume":"42","author":"C Fortuno","year":"2021","unstructured":"Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, Andrade KC, et al. Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat. 2021;42:223\u201336. https:\/\/doi.org\/10.1002\/humu.24152.","journal-title":"Hum Mutat"},{"key":"3202_CR6","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137. https:\/\/doi.org\/10.1038\/s41588-018-0204-y.","journal-title":"Nat Genet"},{"key":"3202_CR7","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function\u2013structure and function\u2013mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci. 2003;100:8424\u20139. https:\/\/doi.org\/10.1073\/pnas.1431692100.","journal-title":"Proc Natl Acad Sci"},{"key":"3202_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.08.013","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell. 2018;71:178-190.e8. https:\/\/doi.org\/10.1016\/j.molcel.2018.08.013.","journal-title":"Mol Cell"},{"key":"3202_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jmedgenet-2020-107059","volume":"58","author":"S Raad","year":"2021","unstructured":"Raad S, Rolain M, Coutant S, Derambure C, Lanos R, Charbonnier F, et al. Blood functional assay for rapid clinical interpretation of germline TP53 variants. J Med Genet. 2021;58:796\u2013805. https:\/\/doi.org\/10.1136\/jmedgenet-2020-107059.","journal-title":"J Med Genet"},{"key":"3202_CR10","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/hmg\/ddx165","volume":"26","author":"Y Zerdoumi","year":"2017","unstructured":"Zerdoumi Y, Lanos R, Raad S, Flaman J-M, Bougeard G, Frebourg T, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26:2812\u20132812. https:\/\/doi.org\/10.1093\/hmg\/ddx165.","journal-title":"Hum Mol Genet"},{"key":"3202_CR11","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2345\u201352. https:\/\/doi.org\/10.1200\/JCO.2014.59.5728.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"3202_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djy001","volume":"110","author":"HQ Rana","year":"2018","unstructured":"Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. Differences in TP53 mutation carrier phenotypes emerge from panel-based testing. JNCI J Natl Cancer Inst. 2018;110:863\u201370. https:\/\/doi.org\/10.1093\/jnci\/djy001.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3202_CR13","doi-asserted-by":"publisher","first-page":"e202000952","DOI":"10.26508\/lsa.202000952","volume":"4","author":"CS Chan","year":"2021","unstructured":"Chan CS, Sun Y, Ke H, Zhao Y, Belete M, Zhang C, et al. Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models. Life Sci Alliance. 2021;4:e202000952. https:\/\/doi.org\/10.26508\/lsa.202000952.","journal-title":"Life Sci Alliance"},{"key":"3202_CR14","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1038\/s41388-021-01892-5","volume":"40","author":"PD Majhi","year":"2021","unstructured":"Majhi PD, Griner NB, Mayfield JA, Compton S, Kane JJ, Baptiste TA, et al. Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome. Oncogene. 2021;40:5026\u201337. https:\/\/doi.org\/10.1038\/s41388-021-01892-5.","journal-title":"Oncogene"},{"key":"3202_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","volume":"30","author":"D Mandelker","year":"2019","unstructured":"Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group. Ann Oncol. 2019;30:1221\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdz136.","journal-title":"Ann Oncol"},{"key":"3202_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jmg.2008.058958","volume":"46","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46:689\u201393. https:\/\/doi.org\/10.1136\/jmg.2008.058958.","journal-title":"J Med Genet"},{"key":"3202_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/jmedgenet-2017-104976","volume":"55","author":"M Renaux-Petel","year":"2018","unstructured":"Renaux-Petel M, Charbonnier F, Th\u00e9ry J-C, Fermey P, Lienard G, Bou J, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet. 2018;55:173\u201380. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104976.","journal-title":"J Med Genet"},{"key":"3202_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/gim.2017.196","volume":"20","author":"JN Weitzel","year":"2018","unstructured":"Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR, et al. Somatic TP53 variants frequently confound germ-line testing results. Genet Med. 2018;20:809\u201316. https:\/\/doi.org\/10.1038\/gim.2017.196.","journal-title":"Genet Med"},{"key":"3202_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12:559\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(11)70119-X.","journal-title":"Lancet Oncol"},{"key":"3202_CR20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17:1295\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(16)30249-2.","journal-title":"Lancet Oncol"},{"key":"3202_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10689-010-9368-z","volume":"9","author":"CRM Lammens","year":"2010","unstructured":"Lammens CRM, Bleiker EMA, Aaronson NK, Wagner A, Sijmons RH, Ausems MGEM, et al. Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer. 2010;9:647\u201354. https:\/\/doi.org\/10.1007\/s10689-010-9368-z.","journal-title":"Fam Cancer"},{"key":"3202_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10689-016-9964-7","volume":"16","author":"KA McBride","year":"2017","unstructured":"McBride KA, Ballinger ML, Schlub TE, Young M-A, Tattersall MHN, Kirk J, et al. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer Netherlands. 2017;16:423\u201332. https:\/\/doi.org\/10.1007\/s10689-016-9964-7.","journal-title":"Fam Cancer Netherlands"},{"key":"3202_CR23","doi-asserted-by":"publisher","first-page":"e27629","DOI":"10.1002\/pbc.27629","volume":"66","author":"CR Tak","year":"2019","unstructured":"Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, et al. Cost-effectiveness of early cancer surveillance for patients with Li\u2013Fraumeni syndrome. Pediatr Blood Cancer. 2019;66:e27629. https:\/\/doi.org\/10.1002\/pbc.27629.","journal-title":"Pediatr Blood Cancer"},{"key":"3202_CR24","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz CP, Achatz MI, Brugi\u00e8res L, Frebourg T, Garber JE, Greer M-LC, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23:e38\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0408.","journal-title":"Clin Cancer Res"},{"key":"3202_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jmedgenet-2020-106876","volume":"58","author":"H Hanson","year":"2021","unstructured":"Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, et al. UKCGG consensus group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. 2021;58:135\u20139. https:\/\/doi.org\/10.1136\/jmedgenet-2020-106876.","journal-title":"J Med Genet"},{"key":"3202_CR26","unstructured":"Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2022 Sep 15]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/ PMID:\u00a020301488"},{"key":"3202_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","volume":"167","author":"K Schon","year":"2018","unstructured":"Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167:417\u201323. https:\/\/doi.org\/10.1007\/s10549-017-4531-y.","journal-title":"Breast Cancer Res Treat"},{"key":"3202_CR28","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet Lond Engl England. 2005;365:1769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)66481-1.","journal-title":"Lancet Lond Engl England"},{"key":"3202_CR29","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/cncr.21863","volume":"106","author":"M Kriege","year":"2006","unstructured":"Kriege M, Brekelmans CTM, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, et al. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer United States. 2006;106:2318\u201326. https:\/\/doi.org\/10.1002\/cncr.21863.","journal-title":"Cancer United States"},{"key":"3202_CR30","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/jamaoncol.2017.1968","volume":"3","author":"ML Ballinger","year":"2017","unstructured":"Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol. 2017;3:1634. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1968.","journal-title":"JAMA Oncol"},{"key":"3202_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1148\/radiol.2021201740","volume":"299","author":"G Petralia","year":"2021","unstructured":"Petralia G, Koh DM, Attariwala R, Busch JJ, Eeles R, Karow D, et al. Oncologically relevant findings reporting and data system (ONCO-RADS): guidelines for the acquisition, interpretation, and reporting of whole-body MRI for cancer screening. Radiol Radiol Soc N Am. 2021;299:494\u2013507. https:\/\/doi.org\/10.1148\/radiol.2021201740.","journal-title":"Radiol Radiol Soc N Am"},{"key":"3202_CR32","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1158\/1078-0432.CCR-17-0515","volume":"23","author":"M-LC Greer","year":"2017","unstructured":"Greer M-LC, Voss SD, States LJ. Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res. 2017;23:e6-13. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0515.","journal-title":"Clin Cancer Res"},{"key":"3202_CR33","doi-asserted-by":"publisher","unstructured":"Summers P, Saia G, Colombo A, Pricolo P, Zugni F, Alessi S, et al. Whole-body magnetic resonance imaging: technique, guidelines and key applications. ecancermedicalscience [Internet]. 2021 [cited 2022 Mar 30];15. Available from: https:\/\/ecancer.org\/en\/journal\/article\/1164-whole-body-magnetic-resonance-imaging-technique-guidelines-and-key-applications doi: https:\/\/doi.org\/10.3332\/ecancer.2021.1164. eCollection 2021.","DOI":"10.3332\/ecancer.2021.1164"},{"key":"3202_CR34","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jamaoncol.2017.1350","volume":"3","author":"PL Mai","year":"2017","unstructured":"Mai PL, Khincha PP, Loud JT, DeCastro RM, Bremer RC, Peters JA, et al. Prevalence of cancer at baseline screening in the national cancer institute Li-Fraumeni syndrome cohort. JAMA Oncol. 2017;3:1640\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1350.","journal-title":"JAMA Oncol"},{"key":"3202_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10689-017-0034-6","volume":"17","author":"J Bojadzieva","year":"2018","unstructured":"Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, et al. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni syndrome education and early detection (LEAD) clinic. Fam Cancer. 2018;17:287\u201394. https:\/\/doi.org\/10.1007\/s10689-017-0034-6.","journal-title":"Fam Cancer"},{"key":"3202_CR36","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3390\/cancers13236111","volume":"13","author":"KCF Tosin","year":"2021","unstructured":"Tosin KCF, Legal EF, Pianovski MAD, Iba\u00f1ez HC, Cust\u00f3dio G, Carvalho DS, et al. Newborn screening for the detection of the TP53 R337H variant and surveillance for early diagnosis of pediatric adrenocortical tumors: lessons learned and way forward. Cancers. 2021;13:6111. https:\/\/doi.org\/10.3390\/cancers13236111.","journal-title":"Cancers"},{"key":"3202_CR37","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1158\/1078-0432.CCR-17-0428","volume":"23","author":"CC Porter","year":"2017","unstructured":"Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, et al. Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res. 2017;23:e14-22. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0428.","journal-title":"Clin Cancer Res"},{"key":"3202_CR38","doi-asserted-by":"publisher","first-page":"a003210","DOI":"10.1101\/mcs.a003210","volume":"5","author":"M Swaminathan","year":"2019","unstructured":"Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, et al. Hematologic malignancies and Li\u2013Fraumeni syndrome. Mol Case Stud. 2019;5:a003210. https:\/\/doi.org\/10.1101\/mcs.a003210.","journal-title":"Mol Case Stud"},{"key":"3202_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104. https:\/\/doi.org\/10.1186\/1748-717X-5-104.","journal-title":"Radiat Oncol"},{"key":"3202_CR40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2018.06.011","volume":"101","author":"E Kasper","year":"2018","unstructured":"Kasper E, Angot E, Colasse E, Nicol L, Sabourin J-C, Adriouch S, et al. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer. 2018;101:254\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.011.","journal-title":"Eur J Cancer"},{"key":"3202_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-020-05612-7","volume":"181","author":"AN Le","year":"2020","unstructured":"Le AN, Harton J, Desai H, Powers J, Zelley K, Bradbury AR, et al. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat. 2020;181:181\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05612-7.","journal-title":"Breast Cancer Res Treat"},{"key":"3202_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10689-019-00153-5","volume":"19","author":"V Petry","year":"2020","unstructured":"Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RNG, Cotti GC, et al. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19:47\u201353. https:\/\/doi.org\/10.1007\/s10689-019-00153-5.","journal-title":"Fam Cancer"},{"key":"3202_CR43","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S1470-2045(21)00425-3","volume":"22","author":"J Thariat","year":"2021","unstructured":"Thariat J, Chevalier F, Orbach D, Ollivier L, Marcy P-Y, Corradini N, et al. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol England. 2021;22:e562\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(21)00425-3.","journal-title":"Lancet Oncol England"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03202-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T07:13:08Z","timestamp":1691997188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03202-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest with respect to the authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval and Informed consent is not necessary for this clinical guideline. The research has been conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}